BrightSpring surges on earnings beat, strong FY26 guidance
Healthcare services provider raises outlook on improving leverage, integration of Amedisys and LHC acquisitions
BrightSpring Health Services shares advanced in Friday trading after the home and community-based healthcare provider delivered fourth-quarter results that handily exceeded analyst expectations and issued an upbeat outlook for fiscal 2026.
The Louisville-based company reported adjusted earnings per share of $0.33, surpassing the Wall Street consensus estimate of $0.26 by 25.2%. Revenue climbed 29.3% to $3.551 billion, beating projections of $3.167 billion. Adjusted EBITDA surged 40.7% year-over-year to $184 million, up from $130 million in the same period a year earlier.
The strong quarterly performance capped a record fiscal year. For full-year 2025, BrightSpring generated $12.91 billion in revenue, a 28.2% increase from the prior year, while net income swung to a profit of $104.8 million compared to a net loss of $68.9 million in 2024. Adjusted EBITDA for the year reached $618 million, representing 34.2% growth. Operating cash flow improved dramatically to $490 million from just $24 million in fiscal 2024.
Perhaps most notably, the company significantly strengthened its balance sheet, reducing leverage to 2.99x net debt to EBITDA as of December 31, 2025, down from 4.16x a year earlier. The improvement came as BrightSpring continued integrating the Amedisys and LHC Group acquisitions, which added 107 home health and hospice branches during the quarter.
Management issued fiscal 2026 guidance that reflects continued momentum and the full-year contribution from recent acquisitions. The company projects revenue between $14.45 billion and $15.0 billion, representing 11.9% to 16.2% growth over fiscal 2025 levels. Adjusted EBITDA is expected to reach $760 million to $790 million, implying 23.1% to 27.9% expansion. The Amedisys and LHC integration alone is forecast to contribute approximately $30 million in adjusted EBITDA during 2026.
Analysts have responded positively to the results and guidance. According to MarketWatch data, BrightSpring maintains a Strong Buy consensus rating from analysts, with an average price target of $44.47, suggesting roughly 11% upside from current levels. The company's forward price-to-earnings multiple of 25.64 reflects optimism about growth prospects, though the stock remains below its 52-week high of $41.40 reached earlier this month.
During the quarter, BrightSpring also returned capital to shareholders through share repurchases. The company bought back 1.5 million shares for approximately $43.2 million, demonstrating confidence in its cash generation capabilities and long-term strategy.
BrightSpring operates two primary segments: pharmacy services and provider services. For 2026, pharmacy revenue is projected to reach $12.6 billion to $13.1 billion, while the provider segment—which includes home health, hospice, and personal care services—is expected to generate $1.85 billion to $1.9 billion, representing robust growth of 26.3% to 29.7%.
The company's focus on value-based care and community-based health services positions it to benefit from demographic tailwinds, including an aging population and healthcare industry shifts toward lower-cost care settings. However, investors will be watching closely for signs of pricing pressure in the pharmacy segment and regulatory changes affecting Medicare reimbursement rates.
BrightSpring's improved leverage ratio and strong operating cash flow generation provide flexibility for further strategic acquisitions or additional share repurchases. With the integration of major acquisitions now largely complete and leverage back within management's target range, the company appears well-positioned to deliver on its growth objectives while returning capital to shareholders.